RayKnowChina Research Map
Shortlist

Beijing

Beijing GoBroad Hospital

北京高博医院

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Beijing GoBroad Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌0 papers led1 open trial led
  2. Hepatocellular carcinoma肝细胞癌0 papers led1 open trial led
  3. Multiple myeloma多发性骨髓瘤0 papers led2 open trials led
  4. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led4 open trials led
  5. IgG4-related diseaseIgG4相关性疾病0 papers led1 open trial led
  6. Myasthenia gravis重症肌无力0 papers led1 open trial led

Not listed for: Nasopharyngeal carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led no English-language PubMed papers on oesophageal squamous cell carcinoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07688291

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  2. Recruiting
    QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07049185

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led no English-language PubMed papers on hepatocellular carcinoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07242417

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  2. Recruiting
    Phase I Study of OriC902 in Treatment of Advanced HCC
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06891742

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  3. Recruiting
    A Study of DEG6498 in Participants With Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07244835

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status3
  1. TC-G203 for Patients With GPC3-Positive Advanced Solid TumorsRecruitingNCT07242417Lead sponsorEarly phase 1Start 2025-12
  2. A Study of DEG6498 in Participants With Solid TumorsRecruitingNCT07244835Study sitePhase 1Start 2025-11
  3. Phase I Study of OriC902 in Treatment of Advanced HCCRecruitingNCT06891742Study sitePhase 1Start 2025-02

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led no English-language PubMed papers on multiple myeloma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07003555

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  2. Recruiting
    Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07003568

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  3. Recruiting
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06182696

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT06326008

    Age 1 year to 18 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  2. Recruiting
    Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06890494

    Age 18 years to 70 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  3. Recruiting
    Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06343090

    Age 1 year to 70 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  4. Recruiting
    CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06389305

    Age 1 year to 39 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07593911

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune DiseasesNot yet recruitingNCT07593911Lead sponsorN/AStart 2026-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07593911

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune DiseasesNot yet recruitingNCT07593911Lead sponsorN/AStart 2026-06

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京高博医院

Beijing GoBroad Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data